Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.

PubWeight™: 0.77‹?›

🔗 View Article (PMID 26625359)

Published in PLoS One on December 01, 2015

Authors

Kristina K Peachman1,2, Nicos Karasavvas3, Agnes-Laurence Chenine1,2, Robert McLinden1,2, Supachai Rerks-Ngarm4, Kaewkungwal Jaranit5, Sorachai Nitayaphan6, Punnee Pitisuttithum7, Sodsai Tovanabutra1,2, Susan Zolla-Pazner8, Nelson L Michael1, Jerome H Kim1, Carl R Alving1, Mangala Rao1

Author Affiliations

1: U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.
2: Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States of America.
3: United States Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
4: Ministry of Public Health, Bangkok, Thailand.
5: Data Management Unit, Mahidol University, Bangkok, Thailand.
6: Royal Thai Army, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
7: Vaccine Trials Center, Mahidol University, Bangkok, Thailand.
8: Veterans Administration New York Harbor Health Care System and NYU School of Medicine, New York, United States of America.

Associated clinical trials:

HIV Vaccine Trial in Thai Adults | NCT00223080

Articles cited by this

Integrins: bidirectional, allosteric signaling machines. Cell (2002) 36.25

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62

Antibody neutralization and escape by HIV-1. Nature (2003) 21.48

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91

Lymphocyte homing and homeostasis. Science (1996) 13.26

Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51

Molecular architecture of native HIV-1 gp120 trimers. Nature (2008) 8.04

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20

Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol (2005) 5.92

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73

Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature (2012) 5.49

HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med (2004) 5.08

HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol (2008) 5.01

Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82

Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61

The immunological synapse. Annu Rev Immunol (2001) 4.45

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature (2012) 3.83

Identification of the residues in human CD4 critical for the binding of HIV. Cell (1989) 3.71

Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol (1994) 2.96

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89

Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog (2010) 2.55

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47

The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog (2011) 2.32

The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A (2009) 2.30

Integrin structures and conformational signaling. Curr Opin Cell Biol (2006) 2.03

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One (2014) 1.97

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One (2013) 1.94

Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88

The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. AIDS Res Hum Retroviruses (2004) 1.88

Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat Struct Mol Biol (2013) 1.80

Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J Virol (2006) 1.76

The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther (2009) 1.73

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One (2013) 1.65

Conserved structural elements in the V3 crown of HIV-1 gp120. Nat Struct Mol Biol (2010) 1.63

Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol (1995) 1.56

Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J Virol (2013) 1.54

V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2001) 1.52

HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV. J Transl Med (2011) 1.45

Expression of HLA class II molecules in humanized NOD.Rag1KO.IL2RgcKO mice is critical for development and function of human T and B cells. PLoS One (2011) 1.41

Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol (2012) 1.37

Blocking of α4β7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J Immunol (2010) 1.33

Targeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection. Nat Med (2014) 1.32

High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas. AIDS Res Hum Retroviruses (1991) 1.17

The frequency of α₄β₇(high) memory CD4⁺ T cells correlates with susceptibility to rectal simian immunodeficiency virus infection. J Acquir Immune Defic Syndr (2013) 1.14

Structural specializations of α(4)β(7), an integrin that mediates rolling adhesion. J Cell Biol (2012) 1.13

Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system. PLoS One (2013) 1.04

Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 binding. PLoS One (2012) 1.03

Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2. PLoS One (2013) 1.00

How natalizumab binds and antagonizes α4 integrins. J Biol Chem (2013) 0.95

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses. EBioMedicine (2014) 0.92

Determination of molecular structures of HIV envelope glycoproteins using cryo-electron tomography and automated sub-tomogram averaging. J Vis Exp (2011) 0.91

Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope. J Virol (2014) 0.91

Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes. PLoS One (2010) 0.89

Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2-V3 interaction and modulates neutralization sensitivity. Proc Natl Acad Sci U S A (2014) 0.87

Envelope glycoprotein binding to the integrin α4β7 is not a general property of most HIV-1 strains. J Virol (2014) 0.86

Estimated secondary structure propensities within V1/V2 region of HIV gp120 are an important global antibody neutralization sensitivity determinant. PLoS One (2014) 0.86

Cryptic determinant of α4β7 binding in the V2 loop of HIV-1 gp120. PLoS One (2014) 0.85

Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV. J Virol (2014) 0.84

Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backbone. PLoS One (2013) 0.83

TFH cells accumulate in mucosal tissues of humanized-DRAG mice and are highly permissive to HIV-1. Sci Rep (2015) 0.83

Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4. AIDS (2009) 0.83

South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication. Retrovirology (2015) 0.82

An anti-phosphoinositide-specific monoclonal antibody that neutralizes HIV-1 infection of human monocyte-derived macrophages. Virology (2012) 0.80

HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development. Curr HIV Res (2013) 0.80

Binding of HIV-1 virions to α4β 7 expressing cells and impact of antagonizing α4β 7 on HIV-1 infection of primary CD4+ T cells. Virol Sin (2014) 0.76